首页 | 本学科首页   官方微博 | 高级检索  
     

《丙型肝炎防治指南 (2019年版)》重要更新要点
引用本文:饶慧瑛,段钟平,王贵强,魏来. 《丙型肝炎防治指南 (2019年版)》重要更新要点[J]. 中华肝脏病杂志, 2020, 0(2): 129-132
作者姓名:饶慧瑛  段钟平  王贵强  魏来
作者单位:北京大学人民医院北京大学肝病研究所;首都医科大学附属北京佑安医院疑难肝病及人工肝中心;北京大学第一医院感染疾病科肝病中心;清华大学附属北京清华长庚医院肝胆胰疾病中心
摘    要:比较了《丙型肝炎防治指南(2019年版)》和以往《丙型肝炎指南》的更新要点。介绍了新的术语。重点强调了世界卫生组织提出的目标——2030年消除病毒性肝炎的公共卫生威胁。在预防部分,将对高危人群进行丙型肝炎病毒感染筛查作为预防的首要手段,强调治疗就是预防。在治疗方面,首先推荐无干扰素的泛基因型方案。还介绍了我国自主研发的直接抗病毒药物,介绍了多个特殊人群的抗病毒治疗方案,包括肝硬化失代偿、慢性肾脏疾病、儿童和青少年、合并慢性肾脏损伤、肝移植前后、合并HBV感染、治疗失败人群、急性丙型肝炎等。介绍了简化的治疗监测流程,特别提到在我国西南地区流行的基因3型。

关 键 词:肝炎,丙型  治疗  预防  指南  要点

Highlights of the guidelines of prevention and treatment for hepatitis C(2019 version)
Rao Huiying,Duan Zhongping,Wang Guiqiang,Wei Lai. Highlights of the guidelines of prevention and treatment for hepatitis C(2019 version)[J]. Chinese journal of hepatology, 2020, 0(2): 129-132
Authors:Rao Huiying  Duan Zhongping  Wang Guiqiang  Wei Lai
Affiliation:(Peking University People’s Hospital,Peking University Hepatology Institute,Beijing 100044,China;Difficult&Complicated Liver Diseases and Artificial Liver Center,Beijing Youan Hospital,Capital Medical University,Beijing 100069,China;Department of Infectious Diseases and Center for Liver Diseases,Peking University First Hospital,Department of Infectious Diseases and Liver,Diseases,Peking University Internatianal Hospital,Beijing 100034,China;Hepatopancreatobiliary Center,Beijing Tsinghua Changgung Hospital,Tsinghua University,Beijing 102218,China)
Abstract:The key points from the updated guideline of prevention and treatment for hepatitis C(2019 version)is compared with the previous hepatitis C guideline.A new terminology and the World Health Organization's goal of eliminating viral hepatitis as a public-health threat by 2030 are stressed.In the prevention section,the screening for hepatitis C virus infection in high-risk population is the primary means of prevention,emphasizing that treatment,is prevention.In the aspect of treatment,pangenotypic interferon-free scheme are initial recommendations.In addition,it also introduces our country independent research and development on direct-acting antiviral agents,and antiviral therapy schedule for many special populations,including decompensated liver cirrhosis,chronic kidney disease,children and adolescents combined with chronic kidney injury,HBV infection-before and after liver transplantation,treatment failure,and acute hepatitis C.A simplified on-treatment monitoring schedule,especially genotype 3 prevalent in Southwest part of our country is introduced.
Keywords:Hepatitis C  Treatment  Prevention  Guidelines  Highlights
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号